NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

NPCE

NeuroPace Inc

Jun 30 • 04:00PM ET

11.14

Dollar change +0.43
Percentage change 4.01	%

Healthcare • Medical Devices • USA • NASD

Peers: MDT BSX SYK PODD LIVN NVRO EW ZBH ISRG STAA

| Held by: VTI IWM VXF IWO VTWO IWC PSC VTWG GSSC RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.83	Insider Own	30.79%	Shs Outstand	32.75M	Perf Week	5.39%
Market Cap	365.38M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	-35.35%	Shs Float	22.70M	Perf Month	-15.03%
Enterprise Value	372.27M	PEG	-	EPS next Q	-0.22	Inst Own	61.07%	Short Float	1.57%	Perf Quarter	-5.99%
Income	-24.80M	P/S	4.33	EPS this Y	11.65%	Inst Trans	-4.70%	Short Ratio	1.03	Perf Half Y	0.00%
Sales	84.31M	P/B	15.03	EPS next Y	27.05%	ROA	-23.73%	Short Interest	0.36M	Perf YTD	-0.45%
Book/sh	0.74	P/C	5.51	EPS next 5Y	31.28%	ROE	-128.49%	52W High	18.98 -41.29%	Perf Year	62.63%
Cash/sh	2.02	P/FCF	-	EPS past 3/5Y	14.21% 5.83%	ROIC	-25.97%	52W Low	5.45 104.40%	Perf 3Y	108.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.93% 16.67%	Gross Margin	74.83%	Volatility	7.17% 6.63%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.42	EPS Y/Y TTM	29.86%	Oper. Margin	-22.86%	ATR (14)	0.92	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.70	Sales Y/Y TTM	22.05%	Profit Margin	-29.42%	RSI (14)	42.11	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.63	EPS Q/Q	33.66%	SMA20	-4.68%	Beta	1.94	Target Price	17.12
Payout	-	Debt/Eq	3.01	Sales Q/Q	24.28%	SMA50	-12.39%	Rel Volume	1.82	Prev Close	10.71
Employees	184	LT Debt/Eq	2.93	Earnings	May 13 AMC	SMA200	2.13%	Avg Volume	346.50K	Price	11.14
IPO	Apr 22, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.83% 2.94%	Trades		Volume	618,100	Change	4.01%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-25	Initiated	H.C. Wainwright	Buy	$18
Jan-21-25	Initiated	UBS	Buy	$17
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$16 → $20
Jan-30-24	Initiated	Leerink Partners	Outperform	$22
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight	$11
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $6
Feb-22-23	Initiated	Lake Street	Buy	$10
Apr-06-22	Initiated	Wolfe Research	Outperform	$13
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$11
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$17 → $12
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform	$26
May-17-21	Initiated	Wells Fargo	Overweight	$25
May-17-21	Initiated	SVB Leerink	Outperform	$25
May-17-21	Initiated	Morgan Stanley	Overweight	$26
May-17-21	Initiated	JP Morgan	Overweight	$27

Show Previous Ratings

Jun-24-25 04:05PM	NeuroPace Announces Strategic CFO Transition (GlobeNewswire)
Jun-17-25 01:35PM	NeuroPace, Inc. (NPCE) Backed by Cantor Fitzgerald Following Physician Survey (Insider Monkey)
Jun-04-25 04:09PM	NeuroPace Secures Up to $75 Million in Debt Financing (GlobeNewswire)
May-29-25 02:48PM	H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating (Insider Monkey) +5.22%
May-28-25 11:50AM	NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial (Zacks)
10:45AM	Loading…
10:45AM	NeuroPace reports initial one-year outcomes from trial of RNS System (Medical Device Network)
May-27-25 12:48PM	Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? (Benzinga) -28.39%
08:00AM	NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study (GlobeNewswire)
May-15-25 08:06AM	5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil (Zacks) +9.49%
May-14-25 12:56PM	Q1 2025 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents) +20.46%
03:15AM	NeuroPace Inc (NPCE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-13-25 05:25PM	NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:23PM	NeuroPace Inc.: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports First Quarter 2025 Financial Results (GlobeNewswire)
08:50AM	Recent Price Trend in NeuroPace (NPCE) is Your Friend, Here's Why (Zacks)
05:15PM	Loading…
May-12-25 05:15PM	DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates (Zacks)
09:33AM	NeuroPace Inc (NPCE) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-09-25 08:20AM	Rapid Micro Biosystems, Inc. (RPID) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 06:15PM	Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-25 05:30PM	Tactile Systems Technology (TCMD) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-14-25 04:05PM	NeuroPace Provides Update on Tariff Status (GlobeNewswire)
Apr-08-25 08:00AM	NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting (GlobeNewswire) -9.76%
Apr-03-25 08:00AM	NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting (GlobeNewswire)
Apr-02-25 04:05PM	NeuroPace Announces Refocusing of Product Portfolio (GlobeNewswire)
Mar-26-25 08:00AM	NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-05-25 06:49AM	Q4 2024 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	NeuroPace Inc (NPCE) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Mar-04-25 04:24PM	NeuroPace Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 09:15PM	UPDATE NeuroPace to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -8.80%
04:05PM	Loading…
04:05PM	NeuroPace to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:14AM	NeuroPace Inc (NPCE) Q4 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Feb-21-25 05:13AM	NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
Feb-20-25 04:05PM	NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. (GlobeNewswire) +5.80%
Feb-19-25 04:05PM	NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (GlobeNewswire)
Feb-18-25 04:05PM	NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +9.18%
Feb-14-25 08:12AM	NeuroPace Prices $65 Million Offering; Shares Drop in Pre-Market (GuruFocus.com)
06:33AM	NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock (GlobeNewswire)
Feb-13-25 04:34PM	NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock (GlobeNewswire)
Feb-03-25 04:05PM	NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th 9th (GlobeNewswire)
Jan-28-25 05:15PM	NeuroPace Issues 2025 Financial Guidance Targets (GlobeNewswire)
Jan-22-25 05:32AM	NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock? (Zacks) +7.50%
Jan-08-25 04:05PM	NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates (GlobeNewswire)
Dec-25-24 12:00PM	NeuroPace (NPCE) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-18-24 04:05PM	NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.64%
Dec-12-24 04:05PM	NeuroPace to Host Investor Day on January 28th in New York City (GlobeNewswire)
Dec-06-24 09:55AM	Wall Street Analysts Think NeuroPace (NPCE) Could Surge 31.47%: Read This Before Placing a Bet (Zacks)
Dec-04-24 04:05PM	NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting (GlobeNewswire) -6.20%
Dec-03-24 04:05PM	NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome (GlobeNewswire) +5.67%
Nov-18-24 12:00PM	What Makes NeuroPace (NPCE) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 54.34%: Here's is How to Trade (Zacks)
Nov-13-24 02:18AM	NeuroPace Inc (NPCE) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth ... (GuruFocus.com) +28.15%
Nov-12-24 06:00PM	NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:54PM	NeuroPace Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance (GlobeNewswire)
Nov-11-24 07:18AM	Earnings To Watch: NeuroPace Inc (NPCE) Reports Q3 2024 Result (GuruFocus.com)
Nov-04-24 04:05PM	NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy (GlobeNewswire) +9.73%
Oct-28-24 09:08PM	KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares (GuruFocus.com)
08:04AM	Strength Seen in NeuroPace (NPCE): Can Its 5.1% Jump Turn into More Strength? (Zacks)
Oct-24-24 09:08PM	KCK LTD. Adjusts Stake in NeuroPace Inc (GuruFocus.com) +5.13%
Oct-22-24 04:05PM	NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
03:01PM	KCK LTD.'s Strategic Reduction in NeuroPace Inc Shares (GuruFocus.com)
Oct-18-24 03:01PM	KCK LTD. Reduces Stake in NeuroPace Inc (GuruFocus.com)
Oct-16-24 04:05PM	NeuroPace Continues to Strengthen Management Team (GlobeNewswire)
Oct-03-24 07:04PM	KCK LTD. Reduces Stake in NeuroPace Inc (GuruFocus.com)
Sep-04-24 04:05PM	NeuroPace Strengthens Management Team with Two Key Appointments (GlobeNewswire)
Aug-27-24 04:05PM	NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-22-24 04:05PM	NeuroPace to Participate in Upcoming Healthcare Conferences in September (GlobeNewswire) -5.65% +12.98%
Aug-20-24 07:37AM	NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up (Zacks)
Aug-13-24 04:05PM	NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance (GlobeNewswire) +5.51% -7.01%
Jul-23-24 04:05PM	NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire) +10.59%
May-14-24 04:05PM	NeuroPace to Participate in Two Healthcare Conferences in May (GlobeNewswire) +6.11%
May-13-24 10:46AM	NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript (Insider Monkey)
06:53AM	Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating (MT Newswires)
May-10-24 03:38PM	NeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing Challenges (GuruFocus.com) +6.65%
May-09-24 03:47AM	NeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ... (GuruFocus.com) -36.75%
May-08-24 04:05PM	NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.26%
Apr-17-24 04:05PM	NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 (GlobeNewswire)
Apr-04-24 12:20PM	Time to Hit Buy, Says Wells Fargo About These 2 Stocks (TipRanks)
Mar-27-24 04:05PM	NeuroPace to Present at the Needham 23rd Annual Healthcare Conference (GlobeNewswire)
Mar-07-24 11:44AM	NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 06:28AM	Q4 2023 Neuropace Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 09:52PM	NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million (GlobeNewswire)
02:00PM	Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio (InvestorPlace)
Feb-23-24 05:15AM	20 Most Valuable Digital Health Companies In The US (Insider Monkey) +11.17%
Feb-15-24 04:05PM	NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (GlobeNewswire)
Feb-07-24 03:13AM	NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares (GuruFocus.com) +5.80%
Feb-01-24 11:02PM	NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares (GuruFocus.com)
Jan-08-24 07:03AM	NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates (GlobeNewswire) +12.89%
Dec-29-23 09:01PM	NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,402 Shares (GuruFocus.com) -5.14%
Dec-21-23 07:07AM	NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study (GlobeNewswire)
Dec-19-23 04:30PM	NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.68% -6.36%
Dec-04-23 05:07PM	NeuroPace to Leverage the Power of its RNS System's Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration (GlobeNewswire) -8.65%
Dec-01-23 08:00AM	NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting (GlobeNewswire)
Nov-21-23 08:00AM	NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-07-23 09:45AM	NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 04:33PM	NeuroPace Inc (NPCE) Reports 47% YoY Revenue Growth in Q3 2023, Raises Full Year Revenue Guidance (GuruFocus.com)
04:03PM	NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance (GlobeNewswire)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ORBIMED ADVISORS LLC	10% Owner	May 14 '25	Sale	15.85	168,136	2,665,333	3,238,199	May 16 05:26 PM
Morrell Martha	CHIEF MEDICAL OFFICER	Feb 21 '25	Sale	13.72	78,334	1,074,844	81,993	Feb 25 06:52 PM
KCK LTD.	10% Owner	Feb 20 '25	Sale	9.40	5,270,845	49,545,943	0	Feb 20 09:51 AM
Morrell Martha	CHIEF MEDICAL OFFICER	Jan 30 '25	Sale	15.00	200	3,000	86,762	Jan 31 07:16 PM
Morrell Martha	CHIEF MEDICAL OFFICER	Jan 29 '25	Sale	15.00	100	1,500	86,962	Jan 31 07:16 PM
MARTHA J MORRELL	Officer	Jan 30 '25	Proposed Sale	14.69	78,534	1,153,664		Jan 30 04:11 PM
MARTHA J MORRELL	Officer	Jan 29 '25	Proposed Sale	14.13	100	1,413		Jan 29 04:26 PM
Morrell Martha	CHIEF MEDICAL OFFICER	Jan 24 '25	Sale	15.01	3,200	48,032	87,062	Jan 28 06:08 PM
MARTHA J MORRELL	Officer	Jan 24 '25	Proposed Sale	14.02	3,200	44,864		Jan 24 04:30 PM
KCK LTD.	10% Owner	Oct 25 '24	Sale	5.45	223,991	1,221,042	5,270,845	Oct 28 03:49 PM
KCK LTD.	10% Owner	Oct 23 '24	Sale	6.02	147	885	5,494,836	Oct 28 03:49 PM
KCK LTD.	10% Owner	Oct 25 '24	Proposed Sale	5.45	223,991	1,221,042		Oct 28 07:02 AM
KCK LTD.	10% Owner	Oct 22 '24	Sale	6.09	4,082	24,853	5,494,983	Oct 24 02:23 PM
KCK LTD.	10% Owner	Oct 18 '24	Sale	6.29	4,878	30,692	5,502,785	Oct 22 10:35 AM
KCK LTD.	10% Owner	Oct 21 '24	Sale	6.10	3,720	22,679	5,499,065	Oct 22 10:35 AM
KCK LTD.	10% Owner	Oct 16 '24	Sale	6.57	6,900	45,336	5,510,957	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 04 '24	Sale	6.92	5,757	39,830	5,545,014	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 08 '24	Sale	6.43	6,000	38,552	5,534,104	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 07 '24	Sale	6.66	4,910	32,687	5,540,104	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 14 '24	Sale	6.54	4,031	26,360	5,521,874	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 15 '24	Sale	6.50	4,017	26,098	5,517,857	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 03 '24	Sale	6.97	3,318	23,115	5,550,771	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 17 '24	Sale	6.28	3,294	20,686	5,507,663	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 09 '24	Sale	6.10	3,123	19,065	5,530,981	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 11 '24	Sale	6.35	2,572	16,320	5,525,905	Oct 18 10:17 AM
KCK LTD.	10% Owner	Oct 10 '24	Sale	6.12	2,504	15,317	5,528,477	Oct 18 10:17 AM
KCK LTD.	10% Owner	Sep 25 '24	Sale	6.60	5,858	38,663	5,578,443	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 26 '24	Sale	6.62	5,821	38,535	5,572,622	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 27 '24	Sale	6.63	5,059	33,541	5,567,563	Oct 03 04:15 PM
KCK LTD.	10% Owner	Aug 30 '24	Sale	7.76	4,314	33,477	5,589,459	Oct 03 04:15 PM
KCK LTD.	10% Owner	Oct 01 '24	Sale	6.77	4,882	33,051	5,557,932	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 30 '24	Sale	6.73	4,749	31,961	5,562,814	Oct 03 04:15 PM
KCK LTD.	10% Owner	Oct 02 '24	Sale	6.87	3,843	26,401	5,554,089	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 03 '24	Sale	7.60	2,093	15,907	5,587,366	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 13 '24	Sale	7.59	1,993	15,127	5,585,348	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 20 '24	Sale	7.50	765	5,738	5,584,583	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 23 '24	Sale	7.54	282	2,126	5,584,301	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 04 '24	Sale	7.50	14	105	5,587,352	Oct 03 04:15 PM
KCK LTD.	10% Owner	Sep 06 '24	Sale	7.50	11	82	5,587,341	Oct 03 04:15 PM
KCK LTD.	10% Owner	Aug 30 '24	Proposed Sale	7.76	190,000	1,474,400		Oct 03 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NPCE

NeuroPace Inc

Upgrade your FINVIZ experience